BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Insulin Pill for Diabetics Seen as $10 Billion Holy Grail for Novo Nordisk A/S (NVO)


5/23/2012 8:37:25 AM

Jackie Chaline needs four shots of insulin a day to survive. The 66-year-old Frenchwoman, who was diagnosed with diabetes 16 years ago, says switching to a pill would be a form of liberation. “Swallowing a tablet would make such a difference,” says Chaline, a former public transport agent who has gotten about 9,000 insulin shots in the past seven years. Novo Nordisk A/S (NOVOB) is trying to make Chaline’s wish, and those of millions more like her, come true. Vying with other drugmakers to develop what could be one of the biggest blockbuster drugs in years, the company is spending at least $2 billion to make an insulin pill hardy enough to cheat the body’s own defense mechanisms and deliver insulin to the bloodstream.

Read at Bloomberg

Bloomberg
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES